Buoyed by rising revenue, the CEO of Scotland's ProStrakan has set his sights on the U.S. market and has raised the possibility of a U.S. acquisition in the next few years. The drug developer has expanded rapidly in Europe in recent years, largely through the acquisition of established sales and marketing groups. ProStrakan has 17 drugs on the market and is preparing to launch two others: Rectogesic for anal fissures and a testosterone gel.
- read this article in The Scotsman for more